Erastin sensitizes Glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1465-1474

  Chen, Liangyu ^a   Li, Xinxing ^a   Liu, Libo ^a   Yu, Bo ^a   Xue, Yixue ^a   Liu, Yunhui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cystathionine lyase; Erastin; Glioblastoma; Temozolomide; XCT

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYSTATHIONINE GAMMA LYASE; CYSTEINE; ERASTIN; GLUTATHIONE; METHIONINE; PROTEIN XCT; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SMALL INTERFERING RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; DACARBAZINE; NFE2L2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; SLC7A11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG SENSITIZATION; EXTRACTION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CYSTATHIONINE GAMMA-LYASE; CYSTEINE; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GLIOBLASTOMA; GLUTATHIONE; HUMANS; NF-E2-RELATED FACTOR 2; PIPERAZINES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFASALAZINE;

EID: 84921647344     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3712     Document Type: Article

References (48)

1. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585-2597, 2000.
2. Gunther W, Pawlak E, Damasceno R, Arnold H and Terzis AJ: Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer 88:463-469, 2003.
3. Knauth M, Wirtz CR, Tronnier VM, Aras N, Kunze S and Sartor K: Intraoperative MR imaging increases the extent of tumor resection in patients with high-grade gliomas. AJNR Am J Neuroradiol 20:1642-1646, 1999.
4. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB and Berens ME: Molecular targets of glioma invasion. Cell Mol Life Sci 64:458-478, 2007.
5. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005.
6. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP and Treasure FP: Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br J Cancer 92:241-245, 2005.
7. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S and Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-2734, 2002.
8. Hegi ME, Diserens A, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352:997-1003, 2005.
9. Conrad M and Sato H: The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 42:231-246, 2012.
10. Sato H, Tamba M, Ishii T and Bannai S: Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274:11455-11458, 1999.
11. Okuno S, Sato H, Kuriyama-Matsumura K, et al: Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer 88:951-956, 2003.
12. Lu SC: Glutathione synthesis. Biochim Biophys Acta 1830:3143-3153, 2013.
13. Ye P, Mimura J, Okada T, et al: Nrf2- and ATF4-dependent up-regulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol 34:3421-3434, 2014.
14. Toyoda M, Kaira K, Ohshima Y, et al: Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer 110:2506-2513, 2014.
15. Yoshikawa M, Tsuchihashi K, Ishimoto T, et al: xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73:1855-1866, 2013.
16. Guo W, Zhao Y, Zhang Z, et al: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett 312:55-61, 2011.
17. Chen RS, Song YM, Zhou ZY, et al: Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 28:599-609, 2009.
18. Gout PW, Buckley AR, Simms CR and Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x (c) - cystine transporter: a new action for an old drug. Leukemia 15:1633-1640, 2001.
19. Robe PA, Martin DH, Nguyen-Khac MT, et al: Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 9:372, 2009.
20. Takeuchi S, Wada K, Nagatani K, Otani N, Osada H and Nawashiro H: Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma. Neurol India 62:42-47, 2014.
21. Yagoda N, von Rechenberg M, Zaganjor E, et al: RAS-RAFMEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447:864-868, 2007.
22. Dixon SJ, Lemberg KM, Lamprecht MR, et al: Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060-1072.
23. Yang WS, SriRamaratnam R, Welsch ME, et al: Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317-331, 2014.
24. Giordana L, Mantilla BS, Santana M, Silber AM and Nowicki C: Cystathionine γ-lyase, an enzyme related to the reverse transsulfuration pathway, is functional in Leishmania spp. J Eukaryot Microbiol 61:204-213, 2014.
25. Romero I, Téllez J, Yamanaka LE, Steindel M, Romanha AJ and Grisard EC: Transsulfuration is an active pathway for cysteine biosynthesis in Trypanosoma rangeli. Parasit Vectors 7:197, 2014.
26. McBean GJ: The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 42:199-205, 2012.
27. Manna P and Jain SK: Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-gamma-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J Biol Chem 287:42324-42332, 2012.
28. Rao AM, Drake MR and Stipanuk MH: Role of the transsulfuration pathway and of gamma-cystathionase activity in the formation of cysteine and sulfate from methionine in rat hepatocytes. J Nutr 120:837-845, 1990.
29. Liu G, Casqueiro J, Bañuelos O, Cardoza RE, Gutiérrez S and Martín JF: Targeted inactivation of the mecB gene, encoding cystathionine-gamma-lyase, shows that the reverse transsulfuration pathway is required for high-level cephalosporin biosynthesis in Acremonium chrysogenum C10 but not for methionine induction of the cephalosporin genes. J Bacteriol 183:1765-1772, 2001.
30. Yang G, Cao K, Wu L and Wang R: Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1. J Biol Chem 279:49199-49205, 2004.
31. Sasaki H, Sato H, Kuriyama-Matsumura K, et al: Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 277:44765-44771, 2002.
32. Wu G, Fang YZ, Yang S, Lupton JR and Turner ND: Glutathione metabolism and its implications for health. J Nutr 134:489-492, 2004.
33. Chung WJ and Sontheimer H: Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem 110:182-193, 2009.
34. Kandil S, Brennan L and McBean GJ: Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and upregulation of the transsulfuration pathway in C6 glioma cells. Neurochem Int 56:611-619, 2010.
35. Hottinger AF, Aissa AB, Espeli V, et al: Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110:2655-2661, 2014.
36. Bartels U, Wolff J, Gore L, et al: Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol 16:1554-1559, 2014.
37. Margison GP and Santibanez-Koref MF: O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24:255-266, 2002.
38. Zhang J, Stevens MF and Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102-114, 2012.
39. She X, Yu Z, Cui Y, et al: miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep 32:957-964, 2014.
40. Lin CJ, Lee CC, Shih YL, et al: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52:377-391, 2012.
41. Yin H, Zhou Y, Wen C, et al: Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncol Rep 32:1610-1616, 2014.
42. Dai L, Cao Y, Chen Y, Parsons C and Qin Z: Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol 7:30, 2014.
43. Doxsee DW, Gout PW, Kurita T, et al: Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67:162-171, 2007.
44. Ehren JL and Maher P: Concurrent regulation of the transcription factors Nrf2 and ATF4 mediates the enhancement of glutathione levels by the flavonoid fisetin. Biochem Pharmacol 85:1816-1826, 2013.
45. Dickhout JG, Carlisle RE, Jerome DE, et al: Integrated stress response modulates cellular redox state via induction of cystathionine gamma-lyase: cross-talk between integrated stress response and thiol metabolism. J Biol Chem 287:7603-7614, 2012.
46. Yang BC, Wang YS, Liu HS and Lin SJ: Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest 80:529-537, 2000.
47. Bermano G, Smyth E, Goua M, Heys SD and Wahle KW: Impaired expression of glutathione peroxidase-4 gene in peripheral blood mononuclear cells: a biomarker of increased breast cancer risk. Cancer Biomark 7:39-46, 2010.
48. Schneider M, Wortmann M, Mandal PK, et al: Absence of Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12/15-lipoxygenase activity. Neoplasia 12:254-263, 2010.